Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03186937 | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer | Phase 2 | terminated | Jun 14, 2017 | University of Wisconsin, Madison | funding and slow enrollment | Enrollment / accrual |
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant…(PrE0801) | Phase 2 | terminated | Jul 25, 2012 | PrECOG, LLC. | Closed due to prolonged enrollment timelines | Enrollment / accrual |
| NCT04085081 | Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer… | N/A | withdrawn | Sep 11, 2019 | City of Hope Medical Center | Funding issue | Funding |
| NCT03988647 | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jun 17, 2019 | Stanford University | Business decision | Sponsor / business decision |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | Phase 1 | terminated | Feb 4, 2019 | George Washington University | Sponsor discontinued the drug | Other (stated, no rule matched) |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line…(MERU) | Phase 3 | terminated | Jan 26, 2017 | AbbVie | Independent Data Monitoring Committee recommendation | Other (stated, no rule matched) |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT04067102 | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for… | N/A | withdrawn | Aug 26, 2019 | Hebei Medical University Fourth Hospital | No patients recruited | Enrollment / accrual |
| NCT01784861 | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With… | Phase 1 / Phase 2 | terminated | Feb 6, 2013 | Washington University School of Medicine | Pharmaceutical company decision | Sponsor / business decision |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | Phase 2 | withdrawn | Jul 1, 2021 | Shanghai Zhongshan Hospital | The standard of care of adjuvant therapy for liver cancer was changed. | Other (stated, no rule matched) |
| NCT01755130 | Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in… | N/A | terminated | Dec 24, 2012 | M.D. Anderson Cancer Center | due to lack of funding | Funding |
| NCT03190213 | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma(Pembro NEC) | Phase 2 | terminated | Jun 16, 2017 | University of Utah | Update on clinical development: after discussions with the drug manufacturer, the PI has decided to… | Drug supply |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 2, 2018 | National Cancer Institute (NCI) | Study was closed after one treatment related death. | Other (stated, no rule matched) |
| NCT03947762 | Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours…(PanNET) | — | terminated | May 13, 2019 | Ipsen | Low enrollment | Enrollment / accrual |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | Phase 1 | terminated | Jun 29, 2017 | University of Chicago | Study stopped due to poor accrual. | Enrollment / accrual |
| NCT03670030 | A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate… | Phase 2 | terminated | Sep 13, 2018 | Robert Ramirez | Slow enrollment | Enrollment / accrual |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | Phase 1 / Phase 2 | withdrawn | Apr 22, 2019 | Sue O'Dorisio | competing clinical trial opening | Other (stated, no rule matched) |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants… | Phase 2 | terminated | Jun 22, 2010 | Agenus Inc. | Sponsor's business decision | Sponsor / business decision |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | Phase 2 | terminated | Dec 16, 2009 | New Mexico Cancer Research Alliance | Low accrual rate | Enrollment / accrual |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced…(PANC-001) | Phase 1 | withdrawn | Feb 17, 2020 | Roger Williams Medical Center | Insufficient accrual rate | Enrollment / accrual |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable…(CIPHER) | Phase 3 | withdrawn | May 24, 2018 | University of Texas Southwestern Medical Center | Due to COVID and other recruitment issues the trial could not be initiated. | COVID-19 / pandemic |
| NCT04073017 | Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality… | N/A | terminated | Aug 28, 2019 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT03875859 | Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma… | Phase 2 | terminated | Mar 15, 2019 | Kavita Sarin | The available study medication reached expiry (logistics). | Other (stated, no rule matched) |
| NCT04250818 | Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on… | — | suspended | Jan 31, 2020 | Texas Tech University Health Sciences Center, El Paso | PI is moving to a new institution | Other (stated, no rule matched) |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT03053284 | Pasireotide in Hyperinsulinemic Hypoglycemia | Phase 2 | withdrawn | Feb 15, 2017 | Montefiore Medical Center | Funding was withdrawn by Sponsor prior to start of study | Funding |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV… | Phase 2 | terminated | Dec 3, 2015 | Henan Cancer Hospital | As there are so many clinical trials in progress and the number of patients enrolled limited. | Enrollment / accrual |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in…(ADHERE) | Phase 3 | withdrawn | Sep 17, 2018 | European Organisation for Research and Treatment of Cancer - EORTC | Company withdrew interest | Sponsor / business decision |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With… | Phase 2 | terminated | Aug 1, 2018 | Chang Gung Memorial Hospital | The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is… | Other (stated, no rule matched) |
| NCT04264754 | Characterization of Methylation Patterns in Hepatocellular Carcinoma | — | terminated | Feb 11, 2020 | Nucleix Ltd. | Sponsor prioritize other clinical projects over this study | Other (stated, no rule matched) |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | Phase 1 | withdrawn | Jun 27, 2007 | University of Maryland, Baltimore | major amendments in progress | Other (stated, no rule matched) |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase 1 / Phase 2 | withdrawn | Jan 16, 2014 | Jazz Pharmaceuticals | Protocol not activated. | Other (stated, no rule matched) |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma,… | Phase 1 / Phase 2 | terminated | Oct 21, 2015 | Dana-Farber Cancer Institute | The study closed primarily due to weak accrual, as well as study design limitations. | Enrollment / accrual |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the…(YES-P) | Phase 3 | terminated | Jun 27, 2013 | Boston Scientific Corporation | Poor Accrual. | Enrollment / accrual |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck… | N/A | terminated | Jun 30, 2014 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT03452553 | Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With… | N/A | withdrawn | Mar 2, 2018 | Boston Scientific Corporation | CMS disapproval, no alternative for sites/patient, risk of financial burden. | Funding |
| NCT01253668 | Brivanib Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Dec 3, 2010 | Abramson Cancer Center at Penn Medicine | In November 2012, this study was permanently closed to new accrual at the request of the drug… | Drug supply |
| NCT01573338 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together… | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Bayer | not stated | Not stated |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated…(Pelican) | Phase 1 | withdrawn | Dec 12, 2018 | Turnstone Biologics, Corp. | insufficient suitable drug supply | Drug supply |
| NCT02853097 | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | — | terminated | Aug 2, 2016 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by… | Phase 1 | withdrawn | Jun 16, 2017 | University of California, Irvine | This study was closed due to extremely low accrual, as well as a change in care when using the… | Enrollment / accrual |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Phase 1 / Phase 2 | withdrawn | Jul 5, 2018 | University of Southern California | No funding | Funding |
| NCT00892255 | Microwave Ablation of Resectable Liver Tumors | — | withdrawn | May 4, 2009 | St. Joseph Hospital of Orange | not stated | Not stated |
| NCT03563274 | QuiremSpheres Observational Study(Hope166) | — | terminated | Jun 20, 2018 | Terumo Europe N.V. | did not meet planned recruitment expectations with a slow recruitment rate | Enrollment / accrual |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | N/A | withdrawn | May 27, 2020 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | Low accrual rate | Enrollment / accrual |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | Phase 3 | withdrawn | Aug 28, 2018 | Istituto Clinico Humanitas | Stopped for internal decisions | Other (stated, no rule matched) |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2014 | Peking University | Because there are questions about adjuvant radiotherapy in this study, the clinical trial is under… | Other (stated, no rule matched) |
| NCT02722369 | STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus… | Phase 2 | terminated | Mar 30, 2016 | University College, London | Low recruitment, lack of efficacy and increased adverse events in investigational arm. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Aug 18, 2021source: clinicaltrials